Essential Evidence POEM of the week reviews a meta-analysis finding no increase risk in adverse CVD outcomes including death, CVD death, MI or Stroke with use of 2nd and 3rd generation sulfonylureas when combined together (glipizide, glimepiride, glibencaminde, plus glicazide ). However, glipizde analyzed alone not in combination with the other sulfonylurea drugs did increase all cause mortality and cardiovascular mortality, this was a sub-analyses based on a small number of patients.
FMEBM - Family Medicine Evidence Based Medicine 